Tvardi Therapeutics (NASDAQ:TVRD) Stock Crosses Above 50 Day Moving Average – Should You Sell?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $1.28 and traded as high as $1.61. Tvardi Therapeutics shares last traded at $1.41, with a volume of 1,863,006 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have commented on TVRD shares. Wall Street Zen downgraded Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, November 1st. Chardan Capital assumed coverage on shares of Tvardi Therapeutics in a research note on Tuesday, October 20th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Finally, BTIG Research lowered their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Trading Up 47.2%

The firm’s fifty day moving average price is $1.28 and its 200-day moving average price is $2.66. The company has a market cap of $18.81 million, a P/E ratio of -0.51 and a beta of 0.37.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, research analysts forecast that Tvardi Therapeutics, Inc. will post -2.23 earnings per share for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Susquehanna International Group LLP acquired a new position in shares of Tvardi Therapeutics in the second quarter valued at $63,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics in the second quarter valued at $34,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.